Rohto Pharmaceutical Co.,Ltd. (4527.T) fair value

ACCE thesis

Rohto Pharmaceutical makes eye drops (Rohto Cool, Rohto Lycee), skin care and sunscreen under its own brands, and it sells them through Japanese drugstores and online channels. Its moat is brand recognition in the Japanese OTC market, where its products sit on the shelf of nearly every pharmacy and its 56.2% gross margin reflects pricing power that generic competitors cannot match. Revenue growth of 11.8% is well above what a mature domestic consumer staples name usually delivers, and it is the number that makes this more than a defensive yield story. Forward earnings at 17.1x against a trailing 20.6x imply the market expects earnings to keep compounding, and at a 14.8% operating margin the company has room to absorb cost inflation without giving up its brand investment. The open question for a deeper look is whether that growth is coming from the core eye care franchise or from the skin care and overseas expansion, since the answer determines how durable the 11.8% is.